ArticleDiabetology & metabolic syndrome2025
Unraveling the causal pathway between phosphatidylinositol, metabolites, and metabolic syndrome: a Mendelian randomization study.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionObservational studies have increasingly acknowledged the influence of Phosphatidylinositol (PI) on metabolic syndrome (MetS). Nevertheless, the causal association between PI and MetS remains unclear due to the presence of confounding factors and the potential for reverse causation in observational settings. This study seeks to clarify the causal link between PI and MetS while investigating the role of mediating metabolites.
methodsA two-sample Mendelian randomization (MR) analysis was performed to examine the association between PI and MetS, utilizing aggregated data from genome-wide association studies (GWAS). Additionally, a two-step MR approach was applied to quantify the mediation effect of metabolites on the PI-MetS relationship. The inverse variance weighted (IVW) method served as the primary analytical approach, complemented by various sensitivity analyses employing alternative techniques.
resultsA significant positive association was found between genetically predicted PI and a 17% increased risk of MetS. Genetically predicted metabolites, including 4-cholesten-3-one (IVW: OR 1.264, 95% CI 1.076-1.483, p = 0.004), N-acetylalliin (IVW: OR 1.189, 95% CI 1.008-1.402, p = 0.040), and the Adenosine 5'-diphosphate to 5-oxoproline ratio (IVW: OR 1.191, 95% CI 1.045-1.357, p = 0.009), were each significantly associated with an increased risks of MetS, accounting for 14.50, 11.41%, 11.87% and % of the total effect, respectively. Notably, the Retinol to oleoyl-linoleoyl-glycerol ratio (IVW: OR 0.643, 95% CI 0.466-0.887, p = 0.007) mediated 62.6% of the effect, highlighting its pivotal role in the causal pathway linking PI to MetS. Moreover, 1-palmitoyl-2-dihomo-linolenoyl-GPC (IVW: OR 0.865, 95% CI 0.752-0.995, p = 0.042) and the Creatine to carnitine ratio (IVW: OR 0.853, 95% CI 0.740-0.983, p = 0.028) were associated with a reduced risk of MetS, demonstrating inhibitory effects within their respective pathways that accounted to 35.03% and 8.45% reductions in risk, respectively.
conclusionsOur MR analysis demonstrated a positive association between PI and an increased risk of MetS. Furthermore, the metabolite-mediated PI significantly influenced MetS risk. These findings may offer valuable insights into the pathogenesis of MetS and inform future clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.